Related Experiment Video

Updated: Aug 16, 2026

A Quantitative Assay to Study Protein:DNA Interactions, Discover Transcriptional Regulators of Gene Expression, and Identify Novel Anti-tumor Agents
06:43

A Quantitative Assay to Study Protein:DNA Interactions, Discover Transcriptional Regulators of Gene Expression, and Identify Novel Anti-tumor Agents

Published on: August 31, 2013

Correlation between VDR expression and antiproliferative activity of vitamin D3 compounds in combination with

Marzena Pelczynska1, Joanna Wietrzyk, Iwona Jaroszewicz

  • 1Department of Experimental Oncology, Institute of Immunology and Experimental Therapy, 12 R. Weigla St., 53-114 Wroclaw, Poland.

Anticancer Research
|September 15, 2005
PubMed

Insights

Vitamin D3 compounds, including calcitriol, enhance chemotherapy by reducing required doses against cancer cells. This synergistic effect is stronger when cancer cells express nuclear vitamin D receptors (nVDR).

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Calcitriol exhibits antiproliferative properties against diverse tumor cells.
  • The biological activity of calcitriol is mediated through vitamin D receptors (VDRs).

Purpose of the Study:

  • To investigate vitamin D3 compounds (calcitriol and PRI-2191) as potential adjuncts in combined antitumour therapy.
  • To assess the synergistic effects of vitamin D3 compounds with cisplatin or doxorubicin.
  • To correlate the observed antitumour effects with nuclear VDR (nVDR) expression.

Main Methods:

  • Utilized antiproliferative SRB and MTT assays to measure growth inhibition.
  • Tested vitamin D3 compounds alone and in combination with cytostatics (cisplatin, doxorubicin).
  • Examined effects across human (HL-60, SW707, A549) and mouse (WEHI-3) cancer cell lines.

Main Results:

  • Combined treatment with vitamin D3 compounds and cytostatics significantly reduced the inhibitory concentration 50% (IC50) values compared to cytostatics alone.
  • The synergistic antitumour effect was positively correlated with the expression of nuclear VDR (nVDR).

Conclusions:

  • Vitamin D3 compounds demonstrate potential as synergistic agents in combined cancer therapy.
  • The efficacy of combined therapy is dependent on the expression levels of nuclear VDR in tumor cells.

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Related Concept Videos

Drug Product Performance: In Vitro–In Vivo Correlation01:20

Drug Product Performance: In Vitro–In Vivo Correlation

In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while adhering...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...